ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

Early Studies Reveal Efficacy, Safety Concerns With Vadastuximab Talirine in Patients With Acute Myeloid...

Wednesday, March 1st, 2017
Early studies of vadastuximab talirine (33A) in patients with acute myeloid leukemia (AML) have shown preliminary efficacy, whether the drug has been used as...

Phase I Study Shows Venetoclax Active in Patients With Relapsed/Refractory Myeloma

Wednesday, March 1st, 2017
The B-cell lymphoma/leukemia-2 (BCL-2) inhibitor venetoclax may be a new option for patients with heavily treated multiple myeloma (MM), according to results from an...

Newly Approved Drugs: How to Use Them in Practice

Wednesday, March 1st, 2017
In 2016, the U.S. Food and Drug Administration (FDA) approved several new therapies for the treatment of hematologic disorders, marking several “firsts” for hematology,...

BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic Mastocytosis

Wednesday, March 1st, 2017
BLU-285, an oral inhibitor of KIT D816V, is well tolerated and could alleviate symptom burden for patients with advanced systemic mastocytosis (SM), according to...

Double Hematopoietic Cell Transplantation Extends Progression-Free Survival Over Single Transplant in Myeloma Patients

Thursday, February 2nd, 2017
Following bortezomib-based induction therapy, patients with newly diagnosed multiple myeloma (MM) who received double autologous hematopoietic cell transplantation (AHCT) had longer progression-free survival (PFS)...

Does the Addition of ATLG Improve Outcomes After Allogeneic Transplantation?

Thursday, February 2nd, 2017
Previous studies have suggested that adding anti-T lymphocyte globulin (ATLG) to the treatment regimen for patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) could reduce...

For Patients on Dialysis With Venous Thromboembolism, Low-Molecular-Weight Heparin May Be a Better Option...

Thursday, February 2nd, 2017
Low-molecular-weight heparins (LMWHs) are not traditionally used to treat venous thromboembolism (VTE) in patients on dialysis, but results from a study presented at the...

Results from Phase III SWOG Trial: 7+3 Still the Standard of Care for Patients...

Tuesday, January 17th, 2017
Remission induction with 7+3 chemotherapy (cytarabine + daunorubicin) should remain the standard of care for younger patients with acute myeloid leukemia (AML), according to...

Large Registry Analysis Confirms Autologous Hematopoietic Cell Transplantation Is Feasible in Older Patients

Tuesday, January 17th, 2017
Older patients (≥65 years) with hematologic malignancies are often considered unsuitable for autologous hematopoietic cell transplantation (AHCT) because of the potential for higher risks...

Balancing Bleeding and Thrombosis Risk With Anticoagulation in Patients With Hematologic Malignancies and Thrombocytopenia

Tuesday, January 17th, 2017
Two studies presented at the 2016 ASH Annual Meeting examined the safety of anticoagulation therapy in patients with hematologic malignancies – a population with...
Advertisement

Current Issue

March 2017, Volume 3, Issue 4

This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.